ArticleHaematologica2024
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ArticleHaematologica2024
Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.